Influenza significantly threatens Canadians aged 65 and older, who comprise the majority of hospitalizations, ICU admissions, and deaths from the virus. Vaccination against influenza is crucial for this age group as it bolsters immune response and reduces the likelihood of severe illness, hospitalization, and mortality. Therefore, adults 65 and older are prioritized for influenza vaccines due to their higher risk. Inactivated high-dose, adjuvanted, or recombinant influenza vaccines are recommended, when available, over other influenza vaccines for this demographic. This program will provide key information about the vaccines indicated for older adults, analyze the supporting evidence for their preferential use, and discuss concurrent administration with other vaccines.
This program has received an educational grant or in-kind support from Sanofi.
